Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuekui Zhang

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Frontiers in Oncology|October 25, 2023
From bench to bedside, 2-in-1 design expedites phase 2/3 oncology drug developmentCong Chen, Xuekui Zhang
The European Respiratory Journal|June 18, 2026
Large scale plasma proteomics: opening up new frontiers of biomarker and therapeutic target discoveries in COPDXuekui Zhang, Don D Sin
Contemporary Clinical Trials Communications|November 30, 2023
A promising biomarker adaptive Phase 2/3 design - Explained and expandedCong Chen, Linda Sun, Xuekui Zhang
Journal of Biomedical Informatics|September 24, 2023
ADSP: An adaptive sample pooling strategy for diagnostic testingXuekui Zhang, Xiaolin Huang, Li Xing
Briefings in Bioinformatics|August 20, 2025
HiCat: a semi-supervised approach for cell type annotationChang Bi, Kailun Bai, Xuekui Zhang
Pharmaceutical Statistics|September 26, 2025
Adjustment for Inconsistency in Adaptive Phase 2/3 Designs With Dose OptimizationCong Chen, Mo Huang, Xuekui Zhang
Journal of Hazardous Materials|November 15, 2025
Paralytic shellfish poisoning risk assessment in the west coast of CanadaChang Bi, Youlian Pan, Xuekui Zhang
Frontiers in Genetics|September 25, 2024
BLESS: bagged logistic regression for biomarker identificationKyle Gardiner, Xuekui Zhang, Li Xing
Contemporary Clinical Trials|August 19, 2025
Adaptive phase 2/3 design with dose optimizationCong Chen, Mo Huang, Xuekui Zhang
BMC Medical Research Methodology|April 8, 2024
Segmentation of patients with small cell lung cancer into responders and non-responders using the optimal cross-validation techniqueElham Majd, Li Xing, Xuekui Zhang
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Frontiers in Oncology|October 25, 2023
From bench to bedside, 2-in-1 design expedites phase 2/3 oncology drug developmentCong Chen, Xuekui Zhang
The European Respiratory Journal|June 18, 2026
Large scale plasma proteomics: opening up new frontiers of biomarker and therapeutic target discoveries in COPDXuekui Zhang, Don D Sin
Contemporary Clinical Trials Communications|November 30, 2023
A promising biomarker adaptive Phase 2/3 design - Explained and expandedCong Chen, Linda Sun, Xuekui Zhang
Journal of Biomedical Informatics|September 24, 2023
ADSP: An adaptive sample pooling strategy for diagnostic testingXuekui Zhang, Xiaolin Huang, Li Xing
Briefings in Bioinformatics|August 20, 2025
HiCat: a semi-supervised approach for cell type annotationChang Bi, Kailun Bai, Xuekui Zhang
Pharmaceutical Statistics|September 26, 2025
Adjustment for Inconsistency in Adaptive Phase 2/3 Designs With Dose OptimizationCong Chen, Mo Huang, Xuekui Zhang
Journal of Hazardous Materials|November 15, 2025
Paralytic shellfish poisoning risk assessment in the west coast of CanadaChang Bi, Youlian Pan, Xuekui Zhang
Frontiers in Genetics|September 25, 2024
BLESS: bagged logistic regression for biomarker identificationKyle Gardiner, Xuekui Zhang, Li Xing
Contemporary Clinical Trials|August 19, 2025
Adaptive phase 2/3 design with dose optimizationCong Chen, Mo Huang, Xuekui Zhang
BMC Medical Research Methodology|April 8, 2024
Segmentation of patients with small cell lung cancer into responders and non-responders using the optimal cross-validation techniqueElham Majd, Li Xing, Xuekui Zhang
Pageof 6